Evelo Biosciences

Evelo develops oral microbiome medicines targeting inflammatory and infectious conditions including C. diff-related research. It uses monoclonal microbial approaches in clinical trials. Relative to OpenBiome it is a venture-backed drug developer with no foundation-style patient access or donation model.